Development of an innovative in vitro potency assay for anti-botulinum antitoxins

Toxins

Volumn 8, Issue 10, 2016, Pages

  Rosen, Osnat ^a   Ozeri, Eyal ^a   Barnea, Ada ^a   David, Alon Ben ^a   Zichel, Ran ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Anti botulinum antibodies; Botulinum; In vitro assay; Potency

Indexed keywords

BOTULINUM ANTISERUM; BOTULINUM TOXIN B; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; PROTEINASE; SYNAPTOBREVIN 1; SYNAPTOTAGMIN; BOTULINUM TOXIN A; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BOTULISM; CATALYSIS; CONTROLLED STUDY; DISEASE SIMULATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; INTERFEROMETRY; LETHALITY; MOUSE; NONHUMAN; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; ANIMAL; BIOASSAY; IMMUNOLOGY; IN VITRO STUDY; METABOLISM;

ANIMALS; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; BOTULINUM ANTITOXIN; BOTULINUM TOXINS, TYPE A; CATALYSIS; ENDOPEPTIDASES; IN VITRO TECHNIQUES; MICE; PEPTIDES;

EID: 84989299970     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8100276     Document Type: Article

References (43)

1. Hatheway, C. Botulism. In Laboratory Diagnosis of Infectious Diseases; Balows, A., Hausler, W.J., Jr., Ohashi, M., Turano, A., Lennete, E.H., Eds.; Springer: New York, NY, USA, 1988; pp. 111–133.
2. Barash, J.R.; Arnon, S.S. A novel strain of clostridium botulinum that produces type B and type H botulinum toxins. J. Infect. Dis. 2014, 209, 183–191. [CrossRef] [PubMed]
3. Turton, K.; Chaddock, J.A.; Acharya, K.R. Botulinum and tetanus neurotoxins: Structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552–558. [CrossRef]
4. Schiavo, G.; Matteoli, M.; Montecucco, C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80, 717–766. [PubMed]
5. Sobel, J. Botulism. Clin. Infect. Dis. 2005, 41, 1167–1173. [CrossRef] [PubMed]
6. Centers for Disease Control and Prevention (CDC). CSTE botulism surveillance summary 2014. Available online: https://www.cdc.gov/nationalsurveillance/pdfs/botulism_cste_2014.pdf (accessed on 19 July 2016).
7. Dong, M.; Yeh, F.; Tepp, W.H.; Dean, C.; Johnson, E.A.; Janz, R.; Chapman, E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312, 592–596. [CrossRef] [PubMed]
8. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M., et al. Botulinum toxin as a biological weapon: Medical and public health managment. J. Am. Med. Assoc. 2001, 285, 1059–1070. [CrossRef]
9. Tacket, C.O.; Shandera, W.X.; Mann, J.M.; Hargrett, N.T.; Blake, P.A. Equine antitoxin use and other factors that predict outcome in type a foodborne botulism. Am. J. Med. 1984, 76, 794–798. [CrossRef]
10. European Directorate for the Quality of Medicines and Healthcare. Botulinum antitoxin. In European Pharmacopoeia, 8th ed.; EDQM Council of Europe: Strasbourg, France, 2014; p. 1029.
11. Dressler, D.; Dirnberger, G. Botulinum toxin antibody testing: Comparison between the immunoprecipitation assay and the mouse diaphragm assay. Eur Neurol. 2001, 45, 257–260. [CrossRef] [PubMed]
12. Hanna, P.A.; Jankovic, J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: Correlation with clinical response. Neurology 1998, 50, 1624–1629. [CrossRef] [PubMed]
13. Lindsey, C.Y.; Smith, L.A.; West, M.W.; Boles, J.W.; Brown, J.E. Evaluation of a botulinum fragment C-based elisa for measuring the humoral immune response in primates. Biologicals 2003, 31, 17–24. [CrossRef]
14. Palace, J.; Nairne, A.; Hyman, N.; Doherty, T.V.; Vincent, A. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology 1998, 50, 1463–1466. [CrossRef] [PubMed]
15. Pellett, S.; Tepp, W.H.; Clancy, C.M.; Borodic, G.E.; Johnson, E.A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581, 4803–4808. [CrossRef] [PubMed]
16. Frisk, M.L.; Lin, G.; Johnson, E.A.; Beebe, D.J. Synaptotagmin II peptide-bead conjugate for botulinum toxin enrichment and detection in microchannels. Biosens. Bioelectron. 2010, 26, 1929–1935. [CrossRef] [PubMed]
17. Wictome, M.; Newton, K.; Jameson, K.; Hallis, B.; Dunnigan, P.; Mackay, E.; Clarke, S.; Taylor, R.; Gaze, J.; Foster, K., et al. Development of an in vitro bioassay for clostridium botulinum type B neurotoxin in foods that is more sensitive than the mouse bioassay. Appl. Environ. Microbiol. 1999, 65, 3787–3792. [PubMed]
18. Kalb, S.R.; Moura, H.; Boyer, A.E.; McWilliams, L.G.; Pirkle, J.L.; Barr, J.R. The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. Anal. Biochem. 2006, 351, 84–92. [CrossRef] [PubMed]
19. Jones, R.G.; Liu, Y.; Rigsby, P.; Sesardic, D. An improved method for development of toxoid vaccines and antitoxins. J. Immunol. Methods 2008, 337, 42–48. [CrossRef] [PubMed]
20. Hallis, B.; James, B.A.; Shone, C.C. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol. 1996, 34, 1934–1938. [PubMed]
21. Rosen, O.; Feldberg, L.; Gura, S.; Brosh-Nissimov, T.; Guri, A.; Zimhony, O.; Shapiro, E.; Beth-Din, A.; Stein, D.; Ozeri, E., et al. Early, real-time medical diagnosis of botulism by endopeptidase-mass spectrometry. Clin. Infect. Dis. 2015, 61, e58–e61. [CrossRef] [PubMed]
22. Boyer, A.E.; Moura, H.; Woolfitt, A.R.; Kalb, S.R.; McWilliams, L.G.; Pavlopoulos, A.; Schmidt, J.G.; Ashley, D.L.; Barr, J.R. From the mouse to the mass spectrometer: Detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal. Chem. 2005, 77, 3916–3924. [CrossRef] [PubMed]
23. Kalb, S.R.; Goodnough, M.C.; Malizio, C.J.; Pirkle, J.L.; Barr, J.R. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics. Anal. Chem. 2005, 77, 6140–6146. [CrossRef] [PubMed]
24. Wang, D.; Baudys, J.; Kalb, S.R.; Barr, J.R. Improved detection of botulinum neurotoxin type A in stool by mass spectrometry. Anal. Biochem. 2011, 412, 67–73. [CrossRef] [PubMed]
25. Bjornstad, K.; Tevell Aberg, A.; Kalb, S.R.; Wang, D.; Barr, J.R.; Bondesson, U.; Hedeland, M. Validation of the Endopep–MS method for qualitative detection of active botulinum neurotoxins in human and chicken serum. Anal. Bioanal. Chem. 2014, 406, 7149–7161. [CrossRef] [PubMed]
26. Kalb, S.R.; Krilich, J.C.; Dykes, J.K.; Luquez, C.; Maslanka, S.E.; Barr, J.R. Detection of botulinum toxins A, B, E, and F in foods by Endopep-MS. J. Agric. Food Chem. 2015, 63, 1133–1141. [CrossRef] [PubMed]
27. Chai, Q.; Arndt, J.W.; Dong, M.; Tepp, W.H.; Johnson, E.A.; Chapman, E.R.; Stevens, R.C. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006, 444, 1096–1100. [CrossRef] [PubMed]
28. Jin, R.; Rummel, A.; Binz, T.; Brunger, A.T. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006, 444, 1092–1095. [CrossRef] [PubMed]
29. Barr, J.R.; Moura, H.; Boyer, A.E.; Woolfitt, A.R.; Kalb, S.R.; Pavlopoulos, A.; McWilliams, L.G.; Schmidt, J.G.; Martinez, R.A.; Ashley, D.L. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg. Infect. Dis. 2005, 11, 1578–1583. [CrossRef] [PubMed]
30. Bowmer, E.J. Preparation and assay of the international standards for clostridium botulinum types A, B, C, D and E antitoxins. Bull. World Health Organ. 1963, 29, 701–709. [PubMed]
31. Food and Drug Administration (FDA). Highlights of prescribing information. Available online: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm345147.pdf (accessed on 19 July 2016).
32. Hatheway, C.H.; Snyder, J.D.; Seals, J.E.; Edell, T.A.; Lewis, G.E., Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E. J. Infect. Dis 1984, 150, 407–412. [CrossRef] [PubMed]
33. Pellett, S.; Du, Z.W.; Pier, C.L.; Tepp, W.H.; Zhang, S.C.; Johnson, E.A. Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem. Biophys. Res. Commun. 2011, 404, 388–392. [CrossRef] [PubMed]
34. Pellett, S.; Tepp, W.H.; Toth, S.I.; Johnson, E.A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 2010, 61, 304–310. [CrossRef] [PubMed]
35. Stahl, A.M.; Ruthel, G.; Torres-Melendez, E.; Kenny, T.A.; Panchal, R.G.; Bavari, S. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: Implications for therapeutic discovery. J. Biomol. Screen. 2007, 12, 370–377. [CrossRef] [PubMed]
36. Shi, J.; Bao, S.; Yin, J.; Cai, K.; Hou, X.; Xiao, L.; Tu, W.; Wang, Q.; Wang, H. Dominant antigenic peptides located at the heavy chain terminal of botulinum neurotoxin B contain receptor-binding sites for synaptotagmin II. Biochem. Biophys. Res. Commun. 2008, 374, 331–335. [CrossRef] [PubMed]
37. Strotmeier, J.; Willjes, G.; Binz, T.; Rummel, A. Human synaptotagmin-ii is not a high affinity receptor for botulinum neurotoxin B and G: Increased therapeutic dosage and immunogenicity. FEBS Lett. 2012, 586, 310–313. [CrossRef] [PubMed]
38. Whelan, S.M.; Elmore, M.J.; Bodsworth, N.J.; Brehm, J.K.; Atkinson, T.; Minton, N.P. Molecular cloning of the clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence. Appl. Environ. Microbiol. 1992, 58, 2345–2354. [PubMed]
39. Zichel, R.; Mimran, A.; Keren, A.; Barnea, A.; Steinberger-Levy, I.; Marcus, D.; Turgeman, A.; Reuveny, S. Efficacy of a potential trivalent vaccine based on hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin. Vaccine Immunol. 2010, 17, 784–792. [CrossRef] [PubMed]
40. European Directorate for the Quality of Medicines and Healthcare. Botulinum antitoxin. In European Pharmacopoeia, 7th ed.; EDQM Council of Europe: Strasbourg, France, 2011; Volume 1, p. 949.
41. Rosen, O.; Feldberg, L.; Gura, S.; Zichel, R. Improved detection of botulinum type E by rational design of a new peptide substrate for endopeptidase-mass spectrometry assay. Anal. Biochem. 2014, 456, 50–52. [CrossRef] [PubMed]
42. Rosen, O.; Feldberg, L.; Gura, S.; Zichel, R. A new peptide substrate for enhanced botulinum neurotoxin type B detection by endopeptidase-liquid chromatography-tandem mass spectrometry/multiple reaction monitoring assay. Anal. Biochem. 2015, 473, 7–10. [CrossRef] [PubMed]
43. Wang, D.; Baudys, J.; Krilich, J.; Smith, T.J.; Barr, J.R.; Kalb, S.R. A two-stage multiplex method for quantitative analysis of botulinum neurotoxins type A, B, E, and F by MALDI-TOF mass spectrometry. Anal. Chem. 2014, 86, 10847–10854. [CrossRef] [PubMed]